Nonsense-mediated mRNA decay (NMD) is an mRNA surveillance mechanism that eliminates aberrant mRNAs containing premature termination codons (PTCs). NMD inhibits the production of aberrant proteins that still retain, at least in part, wild-type function as well as dominant-negative peptides. Therefore, the selective inhibition of NMD has the potential to ameliorate NMD-exacerbated mutant phenotypes. However, we do not have sufficient knowledge of how to effectively suppress NMD with minimum cytotoxic effects. In this study, we aimed to identify NMD-related factors that can be targeted to efficiently inhibit NMD without causing significant cytotoxicity to restore the levels of truncated but partially functional proteins. We evaluated the knockdown of 15 NMD components in Ullrich congenital muscular dystrophy fibroblasts, which have a homozygous frameshift mutation causing a PTC in the collagen type VI α 2 gene. Of the 15 NMD factors tested, knockdown of SMG-8 produced the best effect for restoring defective mRNA and protein levels without affecting cell growth, cellcycle progression, or endoplasmic reticulum stress. The efficacy of SMG-8 knockdown to improve the mutant phenotype was confirmed using another cell line, from a cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy patient who carries a PTC-containing mutation in HtrA serine peptidase 1. Our results suggest that SMG-8 is an appropriate target for inhibiting NMD to improve NMD-exacerbated mutant phenotypes. NMD inhibition by knockdown of SMG-8 may also be useful to induce synergy in combining the use of read-through drugs for patients with nonsense mutation-associated diseases.
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therapy | genetic disorder with premature termination codon | siRNA N onsense-mediated mRNA decay (NMD) is an mRNA quality surveillance mechanism that eliminates aberrant mRNAs carrying premature termination codons (PTCs). Bioinformatics studies have estimated that up to 30% of all known mutations causing human diseases generate aberrant mRNAs that are degraded by NMD (1) (2) (3) (4) . NMD is a double-edged sword, because it degrades not only dominant-negative peptides but also aberrant proteins that retain at least some aspect of their normal cell function. NMD activity plays an important role in the modification of pathological conditions because it determines the fate of aberrant mRNA carrying PTCs through a posttranscriptional mechanism. Truncated proteins, produced by NMD-insensitive transcripts, show gain of function caused by the dominantnegative effects (5, 6) . However, some of the truncated proteins retain normal function, at least partially (7) (8) (9) . When NMD degrades dominant-negative peptides, diseases can be alleviated. However, if NMD degrades aberrant proteins that retain some normal cell function, disease conditions are exacerbated. There are many examples of mutant proteins that are degraded by NMD that retain some residual activity and partially normal function, resulting in an exacerbation of the defects caused by the original mutation (10) (11) (12) (13) .
If mutant proteins are still functional, the selective inhibition of NMD may provide a strategy to ameliorate disease phenotypes in patients with PTC-related conditions. In fact, we have previously shown that NMD inhibition up-regulates the mutant mRNA level and restores, in part, the defect of protein and cellular function in PTC-containing fibroblasts from a patient with Ullrich congenital muscular dystrophy (Ullrich disease) (11, 14) . The patient's fibroblasts have a frameshift mutation in the collagen type VI α 2 gene (COL6A2), which generates PTCcontaining mRNA that can be a target for NMD. The mutant cells failed to assemble triple-helical collagen VI due to the defect in COL6A2 protein. Because type VI collagen is one of the important ECM components maintaining the structural integrity of skeletal muscle, a defect in collagen VI results in dystrophic muscle changes (15, 16) . NMD inhibition caused upregulation of PTC-containing COL6A2 mRNA and protein, resulting in the assembly of triple-helical collagen VI and partial rescue of the mutant phenotype (Fig. S1A ). These observations confirmed that NMD inhibition may provide a novel therapeutic strategy for certain genetic diseases. However, there has been little study, other than our previous report and another study (13) , showing that NMD inhibition has the potential to rescue genetic diseases. Another strategy to inhibit NMD for the rescue of genetic diseases involves drugs causing translational readthrough. A study of translational read-through using gentamicin in cystic fibrosis cells demonstrated that NMD inhibition resulted in a synergistic effect on read-through efficiency (17) . These observations suggest that the manipulation of NMD efficiency can be a potential therapeutic tool. However, some NMD components are essential for mouse development (18) (19) (20) , and inactivation of NMD components causes cell-growth arrest in cancer cell lines (14, 21) . Currently, we do not have sufficient knowledge of how to effectively suppress NMD without causing significant cytotoxicity.
Recent studies have identified more than 20 proteins involved in NMD. The recognition and degradation of aberrant transcripts with PTCs are mediated by sequential remodeling of the multiprotein-mRNA surveillance complex. NMD requires both splicing and translation of the target aberrant mRNA (1) (2) (3) (4) , and requires the exon junction complex (EJC), which is located 20-24 nt upstream of the exon-exon junction during RNA splicing. When the translation complex finds a PTC, an SMG-1-Upf1-eRF1-eRF3 (SURF) complex is formed on the ribosome. If the SURF complex can interact with the downstream EJC, it remodels itself to form the decay-inducing complex (DECID) and causes the degradation of the mRNA (22) (23) (24) (25) . Upf1 is an ATP-dependent mRNA helicase, and SMG-1 is the critical kinase required for the progression of the recognition of the PTC (26) . SMG-1 kinase activity is inhibited by two subunits of the SMG-1 kinase complex, SMG-8 and SMG-9 (24, 27) . SMG-8 is also involved in the recruitment of inactive SMG-1 to the SURF complex. After DECID formation, SMG-1 phosphorylates specific serine residues in Upf1, resulting in the remodeling of the mRNA surveillance complex, enabling it to discriminate between PTC-containing mRNA and normal mRNA (24) . Phosphorylated Upf1 then recruits SMG-5, SMG-6, and SMG-7 and is subsequently dephosphorylated (28, 29) . Sequential phosphorylation and dephosphorylation of Upf1 are thought to be crucial steps in the initiation of NMD.
The above progress on NMD-related factors and the molecular mechanism of NMD prompted us to identify proteins that can be targeted to effectively inhibit NMD while inducing minimum cytotoxicity to rescue the phenotype of PTC-related genetic diseases. In this study, we used Ullrich disease fibroblasts (11, 14) as a model cell line of PTC-related genetic diseases exacerbated by NMD. Among 15 NMD-related factors, we identified that SMG-8 can suppress NMD efficiently with minimum cytotoxic effects. The ability of SMG-8 knockdown to efficiently suppress NMD was confirmed using another PTC-containing cell line from a patient with cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) (12, 30) .
Results

Effect of siRNA-Mediated Knockdown of 15 NMD-Related Factors on
Expression of the Intracellular Collagen VI Triple Helix. To identify a target for the efficient and selective inhibition of NMD, we focused on 15 proteins that have been reported to be involved in NMD. The first group of proteins contains the core NMD components Upf1 and Upf2, which are conserved from human to yeast. The second group contains components of the SMG-1 complex, SMG-1 and its regulator SMG-8. The third group contains SMG-6 and SMG-7, which are required for dephosphorylation of Upf1. The fourth group contains the release factors eRF1, eRF3a, and eRF3b, which are involved in the recognition of the termination codons. The last group contains the core EJC components eIF4A3, Y14, MAGOH/MAGOHB (MAGOH/b), MLN51, and RNPS1 (1-4). To evaluate the potency of RNAi for downregulating NMD-related proteins, we used Ullrich disease fibroblasts, which contain a PTC-generating mutation in CO-L6A2 (11, 14) . The nontreated cell line shows very faint staining using an antibody that selectively recognizes the collagen VI triple helix, whereas knockdown of SMG-1 or Upf1 resulted in strong staining, as reported previously ( Fig. 1) (14) . Silencing of the other NMD components also rescued the mutant phenotype, although the degree of the rescue varied; RNAi of eRF1, eRF3b, or RNPS1 was less effective (Fig. 1) .
Effect of siRNA Knockdown of NMD-Related Factors on Upf1
Phosphorylation and Accumulation of PTC-Containing COL6A2 mRNA.
To confirm that the above effects reflect the inhibition of NMD, we next examined the phosphorylation of Upf1 upon depletion of NMD components. As mentioned above, the process of NMD involves phosphorylation and dephosphorylation of Upf1. Although the phosphorylation status of Upf1 does not exactly parallel NMD inhibition, it provides a useful biochemical measure of NMD status. As expected, knockdown of proteins that are involved before Upf1 phosphorylation-Upf1, Upf2, SMG-1, SMG-8, eRF3a, eIF4A3, Y14, MAGOH/b, and MLN51-suppressed the phosphorylation of Upf1. On the other hand, knockdown of proteins required for Upf1 dephosphorylation, SMG-6 or SMG-7, caused an increase in the phosphorylation of Upf1 ( Fig. 2 A and B) . These results support the notion that all of the siRNAs tested inhibit NMD in Ullrich disease fibroblasts.
To quantitatively evaluate the efficiency of NMD inhibition, we next assessed the accumulation of PTC-containing COL6A2 mRNA by real-time PCR analysis. Knockdown of Upf1, SMG-1, SMG-8, SMG-6, SMG-7, MAGOH/b, or MLN51 caused an increase in PTC-containing COL6A2 mRNA (Fig. 2C ). The functional effect on NMD was evidenced by the up-regulation of an endogenous NMD target, non-protein-coding growth arrestspecific 5 (GAS5) mRNA, harboring PTCs, except SMG-7 (Fig.  S1B ). The result with SMG-7 might be because SMG-6 acts redundantly with the SMG-5-SMG-7 complex for GAS5, as reported (31) . However, knockdown of eRF3a, eIF4A3, Upf2, or Y14 did not show a clear increase in COL6A2 mRNA levels (Fig.  2D ), although NMD suppression was evidenced by up-regulation of CAS5 mRNA harboring PTCs in eRF3a-, Upf2-, or Y14-knockdown cells (Fig. S1C ). The apparent difference between this assay and that shown in Fig. 1 might be caused by differences in the knockdown methods: Synthetic siRNA was used in this experiment, and vector-produced shRNA was used in the experiments presented in Fig. 1 (Fig. S1D ).
Cytotoxic Effect of siRNA Knockdown of NMD-Related Factors. Some NMD-related factors are essential for cell growth during embryogenesis (18) (19) (20) ; therefore, we evaluated whether knockdown of NMD-related factors causes cytotoxicity due to suppression of normal cellular functions. We first analyzed cell growth following knockdown of eight NMD-related factors: Upf1, SMG-1, SMG-8, SMG-6, SMG-7, MAGOH/b, and MLN51. The effect of the knockdown of each NMD-related factor on the growth rate of Ullrich disease fibroblasts was compared with that of epithelioid carcinoma cells (HeLa cells). The growth rates of SMG-8-knocked down cells were not significantly different from those of the nonsilencing siRNA transfectants in either Ullrich disease fibroblasts or HeLa cells (Fig. 3) . In contrast, cell-growth rates of the other seven NMD component-knocked down cells were significantly suppressed at 6 d after siRNA transfection in both cell lines ( Fig. 3 C and D) . Interestingly, growth-rate suppression was much more severe in HeLa cells than in Ullrich disease fibroblasts for all seven proteins. Western blot analyses confirmed knockdown of the respective proteins in HeLa cells (Fig. S2) .
Knockdown of either SMG-1 or Upf1 affects the cell cycle in U2O2 osteosarcoma cells (21, 32) ; therefore, we determined whether knockdown of NMD-related factors affected cell-cycle progression in Ullrich disease fibroblasts and HeLa cells. For both cell lines, cell-cycle distribution analysis by flow cytometry 48 h after transfection of siRNAs showed that knockdown of each of the eight NMD-related factors generated cells with a profile similar to that of nonsilencing siRNA-treated cells. Quantitative analysis revealed that the ratio of G2/M to G0/G1 cells for each NMD component knockdown was not significantly different from that observed in cells treated with nonsilencing siRNA (Fig. S3) .
We then examined whether NMD suppression causes endoplasmic reticulum (ER) stress, because it is possible that the accumulation of aberrant mRNAs by NMD suppression increases the production of unfolded proteins, which leads to ER stress (33) . To test this possibility, we analyzed the expression of ER stress-related proteins, including phosphorylated eIF2α, activating transcription factor 4 (ATF4), and ER chaperone glucoseregulated protein of 78 kDa (GRP78) using NMD-suppressed Ullrich disease fibroblasts and HeLa cells. However, neither of these cell lines showed signs of ER stress responses; ER stressrelated proteins were not up-regulated under NMD suppression, demonstrating that NMD suppression via transfection of siRNAs targeting NMD-related factors does not by itself induce ER stress in these cell lines (Fig. S4) .
Effect of SMG-8 Knockdown on the Accumulation of ECM Collagen VI Protein. The above experiments suggested that SMG-8 is the most appropriate target for suppressing NMD without causing cytotoxicity. To further examine rescue from the mutant phenotype, we evaluated the function of accumulated aberrant collagen VI protein by SMG-8 knockdown. Subconfluent cells were cultured for 6 d in the presence of 0.25 mM ascorbic acid to induce the secretion of triple-helical collagen VI, as performed previously (14) . Immunocytochemistry using an anti-collagen VI antibody revealed much dot-or thread-like staining of collagen VI in the ECM of SMG-8-knocked down cells compared with nonsilencing siRNA transfectants (Fig. 4) . The results suggest that the accumulated aberrant collagen VI protein is secreted and integrated into the ECM in Ullrich disease fibroblasts (Fig.  S1A ). Taken together, these results indicate that depletion of SMG-8 in Ullrich disease fibroblasts rescues the NMD-exacerbated mutant phenotype without causing cytotoxicity.
Effect of NMD Suppression on CARASIL Fibroblasts. To test the general applicability of SMG-8 as a target for selective NMD inhibition, we next examined whether the depletion of SMG-8 rescues the expression of aberrant protein in other mutant cell types. For this purpose, we analyzed another PTC-containing cell line from a patient with CARASIL, which is characterized by cerebral smallvessel arteriopathy with subcortical infarcts, alopecia, and spondylosis (12, 30) . Gene analysis of the case revealed a nonsense mutation with a PTC in the human HtrA serine peptidase 1 (HTRA1) gene (12, 30) . HTRA1 possesses dual activities as chaperones and serine proteases, and represses TGF-β family signaling by binding and cleaving the prodomain of pro-TGF-β1 in the ER, resulting in a reduction of mature TGF-β1 (12) . In this case, mutant PTCmRNA is expected to be degraded by NMD, resulting in an enhancement of TGF-β1 secretion and abnormal TGF-β1 autocrine effects. Thus, NMD inhibition might restore expression of HTRA1 mRNA and protein and cleave the prodomain of pro-TGF-β1, resulting in the suppression of TGF-β1 signaling (Fig. S5A) .
To test this possibility, we first assessed the effect of NMD suppression by the knockdown of Upf1, SMG-1, SMG-8, or SMG-7 on the accumulation of PTC-containing HTRA1 mRNA. Western blot analysis revealed that transfection of siRNA targeting Upf1, SMG-1, SMG-8, or SMG-7 into CARASIL fibroblasts knocked down these proteins. NMD inhibition was estimated by the decrease (in the case of Upf1, SMG-1, and SMG-8 knockdown) or increase (in the case of SMG-7 knockdown) in Upf1 (Fig. 5A) . Real-time PCR analysis showed that knockdown of Upf1, SMG-1, SMG-8, or SMG-7 up-regulated HTRA1 mRNA levels (1.6-to 2.3-fold increase) (Fig. 5B) . Up-regulation of HTRA1 protein was visualized by immunostaining with an anti-HTRA1 antibody (Fig. 5C) .
To evaluate the function of accumulated aberrant HTRA1 protein in CARASIL fibroblasts, we examined the effect of HTRA1 protein on the TGF-β1 pathway (Fig. S5) . Knockdown of SMG-1, SMG-8, or SMG-7, but not Upf1, resulted in accumulation of cleaved inactivated products from pro-TGF-β1, suggesting a decrease in the secretion of mature TGF-β1 (Fig. 6A) . This was supported by a decrease in TGF-β1 signaling, as measured by the phosphorylation status of Smad2 or Smad3 (Fig. 6B) . The functional effect on NMD was evidenced by the up-regulation of an endogenous NMD target GAS5 mRNA harboring PTCs except SMG-7 (Fig. S5B) . In addition, the decreasing of TGF-β signaling caused by SMG-8 knockdown was canceled by the HTRA1 coknockdown. The results provide evidence to prove that NMD inhibition by SMG-8 knockdown does restore HTRA1 (Fig. S5  C and D) . Taken together, these results suggest that accumulation of aberrant HTRA1 protein by knockdown of SMG-1, SMG-8, or SMG-7 rescues the defect in CARASIL fibroblasts. On the other hand, Upf1 knockdown did not alter pro-TGF-β1 cleavage or TGF-β1 signaling. This is probably due to an uncharacterized Upf1-specific function.
Because knockdown of NMD components, except for SMG-8, had a weak cytotoxic effect in Ullrich disease fibroblasts (Fig. 3) , we investigated the cell-growth rate of CARASIL fibroblasts under NMD suppression. As shown in Fig. 6 C and D, cell-growth rates of Upf1-, SMG-1-, and SMG-7-knocked down cells were significantly suppressed at 6 d after the knockdown. In contrast, the growth rate of SMG-8-knocked down cells was not significantly different from that of nonsilencing siRNA transfectants. This result further supports the notion that SMG-8 is a promising target for NMD inhibition to improve NMD-exacerbated mutant phenotypes without affecting cell growth in PTC-containing CARASIL fibroblasts (Fig. S5A ).
Discussion
In this study using two different PTC-containing mutant cell lines, Ullrich disease fibroblasts and CARASIL fibroblasts, we identified SMG-8 as the best target among 15 NMD-related factors examined for NMD inhibition to improve NMD-exacerbated mutant phenotypes without causing cytotoxicity. The two cell lines carried different PTC-generating mutations: a homozygous frameshift mutation in COL6A2 in Ullrich disease fibroblasts, and a nonsense mutation in HTRA1 in CARASIL fibroblasts. The basal level of mRNA abundance in both fibroblasts was around 20% of the wild-type allele (Fig. S6) . We demonstrated that the defects in cellular function due to these different PTC-generating mutations were rescued in part by upregulation of mutated mRNAs and proteins caused by appropriate NMD suppression following knockdown of SMG-8.
Importantly, SMG-8 knockdown did not cause a defect in cell growth in the fibroblasts of either patient or in HeLa cells, in contrast to the other seven NMD factors tested (Figs. 3 and 6 C and D). Our previous study demonstrated a milder effect of SMG-8 knockdown on NMD inhibition in HeLa TetOff cells (24) . The reason why SMG-8 knockdown does not induce suppression of cell growth may be due to a more limited inhibition of NMD compared with the other seven NMD-related factors, although SMG-8 knockdown-induced NMD suppression might vary among cells and tissues. In addition, we observed no effects of SMG-8 knockdown on cell-cycle progression or induction of ER stress in Ullrich disease fibroblasts or HeLa cells (Figs. S3  and S4 ). Furthermore, we have generated a stable SMG-8-knocked down human skeletal muscle cell line (HSkMC) that shows cell growth with a remarkable decrease in phospho-Upf1, which suggested NMD inactivation (Fig. S7A) . Up-regulation of ER stress-related proteins was not observed in this cell line even after 2 mo of culture (Fig. S7B) . From these results, we concluded that SMG-8 is a promising target for efficiently inhibiting NMD to improve NMD-exacerbated mutant phenotypes without affecting essential physiological cell functions. NMD inhibition without causing cytotoxicity may rescue many other patients with PTC-related diseases where the mutant proteins retain some residual activity and partially normal protein functions. Such a strategy might be applicable to some Duchenne muscular dystrophy patients with mutations near the 3′ end of the dystrophin gene (8) and to type 2 long-QT syndrome patients (34) . Furthermore, increases in mRNA levels by SMG-8 knockdown-induced NMD inhibition may bring a synergistic effect on read-through efficiency driven by drugs causing translational read-through (17) .
The severity of cell-growth suppression by NMD inhibition appears to differ between noncancer and cancer cells (Figs. 3  and 6 ). It is possible that the effects of NMD suppression on cellular metabolism are different between noncancer and cancer cells. Although we did not detect any effect of NMD suppression on the cell cycle or on ER stress in HeLa cells (Figs. S2 and S3), it is predicted that survival of some cancer cells is aided by NMD (35, 36) . These mutations are expected to affect not only nonessential genes but also essential genes required for cancer cell survival. NMD can eliminate these aberrant mRNAs with PTCs and can maintain cancer cell homeostasis (36) . Remarkable suppression of cell growth in NMD-inhibited HeLa cells (Fig. 3D ) may be due to the disturbance of cell homeostasis. In addition, unnatural polypeptides synthesized from mutated mRNAs with PTCs may act as antigens on the surface of cancer cells, which could potentially activate the antitumor immune system if they are not eliminated by NMD (35, 37) . Based on these observations, NMD repression may be a potential therapeutic target for certain cancers. Occurrence of NMD usually depends on the location of PTCs. Normal termination codons or PTCs in the last exon do not efficiently elicit NMD, because at least one intron downstream of a PTC is required to strongly promote NMD in mammalian cells (1) (2) (3) (4) . In general it is thought that an aberrant mRNA carrying a PTC that is located more than ∼55 nt upstream of the last exonexon junction is targeted by NMD (1-4) . However, there have been many clinical cases where the location of PTC mutations is not consistent with the above finding (1-4). Kerr et al. reported muscular dystrophy cases carrying the same PTC mutation in the dystrophin gene, but with different phenotypes: severe Duchenne muscular dystrophy or milder Becker muscular dystrophy (8) . Furthermore, it has been reported that NMD activity differs among tissues (38, 39) as well as cell lines (40, 41) , whereas the stabilities of PTC-mRNAs encoding aberrant proteins are alleledependent in human cultured cells (11, 26, 42) . These findings strongly indicate that there are additional factors that affect the phenotypes of PTC-generating mutations. From our findings that knockdown of 15 NMD factors showed different effects on NMD activity, rescue of mutant mRNAs and proteins, and cellular function defects, we suggest that the additional factors may include polymorphisms in genes encoding NMD-related factors or their regulators, or reflect their different expression levels in different cellular contexts.
In conclusion, we identified SMG-8 as a promising target for efficient and selective NMD inhibition to restore partially functional truncated peptides in PTC-related, NMD-exacerbated diseases. There may also be synergy in combining NMD inhibition by knockdown of SMG-8 and the use of read-through drugs for patients with nonsense mutation-associated diseases.
Materials and Methods
Patients and cell culture were described in SI Materials and Methods. SI Materials and Methods also provides details for siRNA preparation and transfection, real-time quantitative PCR, Western blot analysis, and antibodies. See SI Materials and Methods for analyses of immunocytochemistry, flow cytometry for cell cycle, and cell growth.
